Genitourinary Cancer News

Limiting eligibility criteria, recruiting trusted community messengers and reducing financial burdens can help improve diversity of clinical trial enrollees, a panel of professionals said during a Friends of Cancer Research webinar.

Use of subjective minimizing terminology, such as “safe” and “tolerable,” when discussing treatment-related toxicities occurs frequently at oncology and hematology conferences, according to a study published in Journal of Cancer Policy.

Patients who underwent cancer surgery had an increased risk for venous thromboembolism for up to 1 year after the procedure, results from a retrospective study published in JAMA Network Open showed.

Adjuvant therapy with pembrolizumab following nephrectomy conferred significant improvement in OS compared with placebo among adults with renal cell carcinoma who had a high risk for disease recurrence, study results showed.

As the broader health care field strives to identify and address health care disparities, a commentary published in The Lancet Oncology underscored the importance of eliminating ableism from cancer care.

The proportion of individuals with newly diagnosed cancer who lacked insurance in the U.S. declined significantly from 2010 to 2019, according to data published in Health Affairs Scholar.

Subcutaneous nivolumab can reduce burdens on the health care system and patients with pretreated advanced or metastatic clear cell renal cell carcinoma compared with its IV formulation, according to data from a phase 3 CheckMate 67T trial.

The addition of immunotherapy to perioperative conventional cancer therapy appeared linked to more grade 3 to grade 4 treatment related adverse events, according to findings published in The Lancet Oncology.

Health care professionals who experienced recent weight loss had a significantly higher risk for a cancer diagnosis during the subsequent 12 months, results of a prospective cohort analysis revealed.

The FDA approved erdafitinib (Balversa, Janssen Biotech) for adults with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, according to a press release.